Dabigatran and warfarin: comparative analysis of safety and cost.

被引：0
|
作者：
Vakil, Niyati H. [1 ]
Leber, Molly [1 ]
Bliss, Gina [1 ]
Yazdi, Marina [1 ]
机构：
[1] Yale New Haven Med Ctr, New Haven, CT 06504 USA
来源：
PHARMACOTHERAPY | 2012年 / 32卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
6E
引用
收藏
页码：E179 / E179
页数：1
相关论文
共 50 条
  • [21] Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China
    Hongtao Wei
    Can Cui
    Xiangli Cui
    Yi Liu
    Dandan Li
    BMC Health Services Research, 21
  • [22] Application Value and Safety Analysis of Warfarin, Rivaroxaban, and Dabigatran Ester in Elderly Patients With Atrial Fibrillation
    Chen, Cheng
    Tian, Qing
    Cheng, Chong
    Ji, Xixin
    Feng, Mengyun
    Tan, Huiqun
    Zhou, Qian
    CLINICAL CARDIOLOGY, 2024, 47 (09)
  • [23] Dabigatran versus warfarin
    Laffman-Johnson, Elise
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (03) : 252 - 252
  • [24] COST EFFECTIVENESS OF APIXABAN, DABIGATRAN RIVAROXABAN AND WARFARIN FOR ATRIAL FIBRILLATION IN GUATEMALA
    Garita, M.
    Peralta, M.
    Gordillo, D., I
    VALUE IN HEALTH, 2014, 17 (03) : A115 - A115
  • [25] Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation
    Seeger, John D.
    Bykov, Katsiaryna
    Bartels, Dorothee B.
    Huybrechts, Krista
    Zint, Kristina
    Schneeweiss, Sebastian
    THROMBOSIS AND HAEMOSTASIS, 2015, 114 (06) : 1277 - 1289
  • [26] Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis
    Ali, Ali
    Bailey, Claire
    Abdelhafiz, Ahmed H.
    AGE AND AGEING, 2012, 41 (05) : 681 - 684
  • [27] Cost-effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China
    Wei, Hongtao
    Cui, Can
    Cui, Xiangli
    Liu, Yi
    Li, Dandan
    BMC HEALTH SERVICES RESEARCH, 2021, 21 (01)
  • [28] Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
    Chieh-Yu Liu
    Hui-Chun Chen
    Clinical Drug Investigation, 2017, 37 : 285 - 293
  • [29] COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN COMPARED TO WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION IN A MEDICARE POPULATION
    Ward, M. A.
    Biddle, A. K.
    VALUE IN HEALTH, 2012, 15 (04) : A121 - A121
  • [30] Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
    Liu, Chieh-Yu
    Chen, Hui-Chun
    CLINICAL DRUG INVESTIGATION, 2017, 37 (03) : 285 - 293
12345